FCR 001

Drug Profile

FCR 001

Alternative Names: Facilitating Cell Therapy - Novartis/Regenerex; FCR001; FCRx - Novartis/Regenerex; Haematopoietic stem cell therapies - Novartis/Regenerex

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regenerex LLC
  • Developer Novartis; Regenerex LLC; University of Louisville
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Renal transplant rejection

Most Recent Events

  • 27 Jan 2017 Discontinued - Phase-II for Renal transplant rejection (Prevention) in USA (IV) (Novartis 20-F filed in 2017)
  • 14 Jul 2016 FCR 001 is still in phase II trials for Renal transplant rejection in USA (IV, Infusion) (NCT00497926)
  • 20 Jun 2014 Novartis announces its commitment to advancing its cell therapy portfolio, including the FCRx platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top